Astrana Health, Inc. (ASTH) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Astrana Health, Inc. is a provider-centric, technology-powered, risk-bearing healthcare company operating in California, Nevada, and Texas. The company manages care for approximately 1.0 million patients through a network of over 10,000 contracted physicians. Operations are organized into three segments: Care Partners (risk-bearing organizations), Care Delivery (clinics and ancillary services), and Care Enablement (management services and technology).
Key Financial Metrics (Nine Months Ended Sept 30, 2024)
| Metric | 2024 (9 Months) | 2023 (9 Months) | Change |
|---|---|---|---|
| Total Revenue | $1,369.3 million | $1,033.6 million | +32% |
| Net Income (Astrana) | $50.1 million | $48.4 million | +4% |
| Diluted EPS | $1.04 | $1.03 | +1% |
| Operating Income | $88.6 million | $88.5 million | Flat |
| Adjusted EBITDA | $135.3 million | $117.6 million | +15% |
| Cash & Equivalents | $348.0 million | $294.2 million | +18% |
| Total Debt | $441.9 million | $282.0 million | +57% |
Note: Revenue growth was primarily driven by capitation revenue (+37%) due to recent acquisitions and increased risk-bearing enrollment.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by $335.7 million (32%) year-over-year. Capitation revenue grew by $333.5 million, driven by the acquisition of CFC IPA assets (Jan 2024) and Restricted Knox-Keene licensed health plans (Mar 2024).
- Expense Increases: Cost of services rose 34% to $1.15 billion, and G&A expenses increased 51% to $112.5 million, reflecting operational scale and integration costs from acquisitions.
- Interest Expense: Interest expense surged 134% to $25.0 million due to increased borrowings on the Amended Credit Facility to fund acquisitions.
- Acquisitions: The company completed several acquisitions in the first nine months of 2024, including Community Family Care Medical Group (CFC), Advanced Health Management Systems (AHMS), and Airline Complete Healthcare, contributing $235.9 million in revenue and $26.4 million in net income post-acquisition.
Guidance, Outlook, and Risks
2024 Full-Year Guidance (Updated):
- Total Revenue: $1,950 million – $2,030 million
- Net Income (Astrana): $52 million – $58 million
- Adjusted EBITDA: $165 million – $175 million
- Diluted EPS: $1.06 – $1.19
Strategic Transactions:
- Prospect Medical Holdings: On November 8, 2024, Astrana entered an agreement to acquire certain assets and businesses of Prospect Medical Holdings for an aggregate purchase price of $745.0 million. The transaction is expected to close in mid-2025, subject to regulatory approvals.
- Financing: A commitment letter was secured for a $1.095 billion bridge term loan and a $100 million revolving credit facility to fund the Prospect transaction.
Risks and Contingencies:
- Transaction Risk: The Prospect acquisition is subject to customary closing conditions and regulatory approvals; failure to close could adversely affect the stock price and business plans.
- Debt Load: Financing the Prospect transaction will significantly increase indebtedness and interest expenses.
- Regulatory: As a risk-bearing organization, the company is subject to complex Medicare/Medicaid regulations and potential government reviews.
Investor Verification Checklist
- Acquisition Integration: Verify the realization of synergies and revenue contributions from recent acquisitions (CFC, AHMS, CHS) against guidance.
- Debt Covenants: Monitor compliance with the Amended Credit Agreement leverage ratios (max 3.75:1, temporarily 4.0:1 for acquisitions) given the increased debt load.
- Prospect Transaction Status: Track regulatory approval progress for the $745 million Prospect acquisition and the execution of the $1.1 billion bridge financing.
- Capitation Trends: Analyze the sustainability of the 37% capitation revenue growth and the impact of transitioning enrollees to full risk.
- Medical Liabilities: Review the $160.3 million medical liability balance and the adequacy of reserves for incurred but not reported claims.